Am I eligible to apply?
- At the time of submission, applicants must be a citizen of a country in which Team PHenomenal Hope has an active chapter: currently, those countries are the United States, Germany, Brazil, South Africa, and Mexico.
- Applicants may be physicians, nurses, pharmacists, or allied health professionals; however, the proposal must address an issue/question in the field of pulmonary hypertension - whether at the level of basic science, translational science, clinical research/care, health policy, etc.
- These grants are expected to fund an individual early in his/her career or as an initial grant to investigate a particular subject (especially if a non-physician); these grants are not meant for “experienced” applicants. For example, for a physician, it should be clear that the applicant is at the early phase of his/her career - no more than 5 years of experience beyond his/her first faculty appointment at the start of the award (7/2019).
- An applicant will be disqualified if he/she has significant funding from other government or corporate sources. Likewise, there can be no significant scientific nor financial overlap between this grant and other funded projects.
- Applicants may not be an employee of a commercial entity (eg, pharmaceutical company).
- If you have extenuating circumstances and do not meet the eligibility criteria but have a grant you believe would be fundable, please contact us at research@teamphenomenalhope.
How do I apply?
The application process is simple:
- Submit a Letter of Intent (LOI) proposal with a brief introduction, background, hypothesis and objectives, and specific aims to achieve these objectives. The LOI is due February 1, 2019.
- If the LOI is selected, submit a full grant - the full grant will be due March 15, 2019.
Are there other things I should know?
- Further information about Team Phenomenal Hope and our programs are available on the website (www.teamphenomenalhope.org)
- The focus of the grant/proposal should be to develop a better understanding of/approach to disorders of pulmonary vascular biology (pulmonary hypertension)
- Bridge funding, therapeutic drug trials, or registry trials will not be funded.
- Co-investigators may be included; if so, the specific role of each co- investigator and any allocation of funds to this individual(s) must be enumerated.
- Funds will not be awarded to individuals whose salaries are largely derived from commercial organizations in the pharmaceutical or allied industries. That said, research support from commercial organizations is allowed.
- Funds are not institution- or site-specific, but are specific to the project and the principal investigator. Should the principal investigator relocate during the course of the project, the Program may fund remaining amounts to the principal investigator if he/she can demonstrate to the Steering Committee that the project can be properly completed as proposed at the new site.
- In there are questions or issues that require clarification, please contact us via the website.